Metabolic Syndrome and Breast Cancer Prognosis
Author Information
Author(s): Ma Youzhao, Zhang Jingyang, Jiao Dechuang, Chen Xiuchun, Liu Zhenzhen
Primary Institution: The Affiliated Cancer Hospital of Zhengzhou University & Henan Cancer Hospital
Hypothesis
This study aimed to investigate the impact of metabolic syndrome on the prognosis of patients with breast cancer undergoing neoadjuvant therapy.
Conclusion
Metabolic syndrome was associated with poor prognosis in patients with breast cancer receiving neoadjuvant therapy.
Supporting Evidence
- Metabolic syndrome was diagnosed in 18.0% of the patients.
- Patients with metabolic syndrome had a lower pathological complete response rate.
- The 5-year disease-free survival was significantly better in the non-metabolic syndrome group.
Takeaway
Having metabolic syndrome makes it harder for breast cancer patients to get better after treatment.
Methodology
The study analyzed data from breast cancer patients receiving neoadjuvant therapy between January 2017 and December 2019, using statistical models to assess survival outcomes.
Potential Biases
Potential treatment compliance differences among patients with metabolic syndrome-related diseases may affect results.
Limitations
The study was a single-center retrospective analysis and lacked waist circumference data.
Participant Demographics
The median age at diagnosis was 49 years, with 574 premenopausal and 336 postmenopausal women.
Statistical Information
P-Value
p=0.001
Confidence Interval
95% CI: 1.201–2.421
Statistical Significance
p<0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website